Tazemetostat is a small molecule selective and S-adenosyl methionine competitive inhibitor of histone methyltransferase EZH237 with anti-neoplastic activity that is FDA approved for epithelioid sarcoma and follicular lymphoma. Here, PRDM9 is linked to follicular lymphoma.